MolecLink™ Platform

Integrating rational molecular coupling with localized delivery to create safe, effective, and long-acting therapies.

Platform Overview

MolecLink™ Platform: Molecular Conjugation Platform Enabling Site-Specific Localized Drug Delivery

Current drug development often faces challenges in balancing therapeutic efficacy, tissue targeting, and systemic safety, especially for localized diseases requiring sustained action at the lesion site. To overcome these limitations, Protheragen has independently developed the MolecLink™ technology platform, an advanced molecular assembly and conjugation system designed to create innovative, site-specific therapeutic agents. By integrating rational molecular coupling with optimized local delivery formulations, the platform enables highly effective, well-tolerated, and long-acting therapies that address significant unmet clinical needs.

Disruptive Technology
Excellent Team
Diversified Pipeline
Customized Solutions

Platform Core

Proprietary Molecular Conjugation and Controlled Assembly Technology

The MolecLink™ platform is built on proprietary molecular coupling and controlled assembly technology, which covalently links active pharmaceutical ingredients (APIs) with functional molecular carriers or polymeric scaffolds in a highly controllable manner. This core design ensures that the conjugated molecules maintain their biological activity while achieving targeted delivery and sustained release.

Platform Advantages

Unique Advantages of the MolecLink™ Platform

Superior Targeting Efficiency

MolecLink™ enables precise localization of therapeutics to diseased tissues through targeted molecular coupling, significantly increasing local drug concentration while reducing off-target distribution and systemic side effects, maximizing therapeutic benefits.

Enhanced Safety Profile

By minimizing systemic absorption of drugs and maintaining controlled, slow release at the lesion site, the platform greatly lowers systemic toxicity, improves patient tolerability, and enhances long-term treatment compliance.

Versatile Nucleic Acid Cargo Compatibility

Sustained Therapeutic Action

The unique molecular assembly structure of MolecLink™ supports slow and sustained drug release, prolonging the duration of therapeutic action, reducing the frequency of administration, and alleviating the burden on patients.

Broad Formulation Compatibility

The platform has strong adaptability and is compatible with multiple local delivery dosage forms, including intracavitary injection, subcutaneous injection, topical gels, and inhalation aerosols, supporting flexible drug development across multiple therapeutic areas.

Platform Application

Advancing Localized Delivery Across Multiple Dosage Forms

Local Injectable Therapies MolecLink™ supports the development of long-acting injectable drugs for joint diseases, intraocular disorders, intracavitary lesions, and soft-tissue diseases, enabling durable therapeutic efficacy with fewer injections and improving patient experience.
Topical Dermatological Formulations By optimizing molecular coupling and skin penetration technology, MolecLink™ enhances the skin retention and bioavailability of topical drugs, which is suitable for the treatment of inflammatory skin diseases such as psoriasis and eczema, ensuring deeper delivery and longer residence time.
Respiratory & Inhalation Therapies The platform enables the development of optimized aerosol formulations for pulmonary diseases (such as chronic obstructive pulmonary disease and asthma), realizing targeted delivery to the lungs, reducing systemic exposure, and improving the safety and efficacy of treatment.

Pipeline

Research & Development Pipeline

Project	Dosage Form	Indication
MLK001	Long-acting Injectable	Rheumatoid Arthritis
MLK007	Topical Gel	Psoriasis
MLK013	Inhalation Aerosol	Chronic Obstructive Pulmonary Disease
MLK015	Sustained-release Implant	Localized Solid Tumors

Get in Touch with Us

FAQs

Frequently Asked Questions

Q1: How does MolecLink™ differ from traditional drug delivery platforms? A: Unlike traditional systemic drug delivery platforms, MolecLink™ focuses on site-specific molecular coupling and controlled release, maximizing the local therapeutic effect while minimizing systemic exposure, effectively solving the problem of low targeting and high side effects of traditional drugs.
Q2: What types of molecules can be applied to the MolecLink™ Platform? A: The platform has strong compatibility and supports the coupling of small molecules, peptides, and selected biological agents, which can be stably conjugated to develop localized delivery drugs.
Q3: Can the MolecLink™ Platform support the development of sustained-release formulations? A: Yes. The unique molecular assembly structure of the platform enables controlled and prolonged drug release, which can significantly extend the duration of therapeutic action and reduce the frequency of administration.
Q4: What dosage forms can be developed based on the MolecLink™ Platform? A: The platform is compatible with multiple local delivery dosage forms, including intracavitary injection, subcutaneous injection, topical preparations, inhalation aerosols, and implantable systems, meeting the needs of different therapeutic scenarios.
Q5: Is the MolecLink™ Platform suitable for the development of drugs for inflammatory diseases? A: Yes. The platform is especially suitable for chronic inflammatory diseases, degenerative diseases, and local lesions that require sustained local action, and can effectively improve the therapeutic effect of such diseases.
Q6: Does Protheragen provide custom development services based on the MolecLink™ Platform? A: Yes. We provide integrated CRO/CDMO services based on the MolecLink™ Platform, including molecular design, molecular coupling, formulation development, and preclinical evaluation, to meet the personalized needs of customers.